| Product Unit Size | Cost | Quantity | Stock |
|---|
BI-6727 is a polo-like kinase 1 (PLK1) inhibitor that exhibits anticancer activity. In vitro, BI-6727 induces apoptosis in acute myelogenous leukemia (AML) cells. This compound is currently in clinical trials as a potential treatment for several cancers; it improves response and survival rates.
| Cas No. | 755038-65-4 |
|---|---|
| Purity | ≥99% |
| Formula | C34H50N8O3 |
| Formula Wt. | 618.81 |
| IUPAC Name | N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide |
| Synonym | BI6727, Volasertib |
| Solubility | DMSO 20 mg/mL warmed (32.32 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White to off white powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Münch C, Dragoi D, Frey AV, et al. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines. Leuk Res. 2015 Jan 28. [Epub ahead of print]. PMID: 25697066.
Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 2015 Jan;29(1):11-9. PMID: 25027517.
Lin CC, Su WC, Yen CJ, et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer. 2014 May 13;110(10):2434-40. PMID: 24755882.